Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

No abstract is available for this paper.

• Publication year

  2013

• Venue

  HIV Clinical Trials

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1310/hct1405-192PMID 24144896
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.

  2013cited by this paper
• Attitudes and Acceptance of Oral and Parenteral HIV Preexposure Prophylaxis among Potential User Groups: A Multinational Study

  2012cited by this paper
• Efavirenz

  2012cited by this paper
• Efavirenz

  2012cited by this paper
• The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

  2012cited by this paper
• Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

  2011cited by this paper
• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

  2011cited by this paper
• In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

  2010cited by this paper
• Efavirenz in the therapy of HIV infection

  2010cited by this paper
• Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

  2009cited by this paper
• Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

  2009cited by this paper
• Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients

  2009cited by this paper
• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  2008cited by this paper
• Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

  2006cited by this paper
• A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

  2003cited by this paper
• ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

  2001cited by this paper
• Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

  1998cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• Infection and Drug Resistance Dovepress Patterns of Resistance Development with Integrase Inhibitors in Hiv

  year unknowncited by this paper

• HIV Infection, Neurotoxicity, Inflammation, Premature Aging, and Therapeutic Challenges to PLWH: An Overview

  2026cites this paper
• Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile

  2025cites this paper
• Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

  2025cites this paper
• Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long‐Acting Intramuscular Injections

  2025cites this paper
• Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084

  2025cites this paper
• Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report

  2025influential citation
• A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

  2025cites this paper
• Estimation of prevention-effective CAB-LA concentrations among men who have sex with men (MSM) and transgender women (TGW) in HPTN 083.

  2025cites this paper
• A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy

  2025cites this paper
• Development and validation of a new lc-ms/ms method for the determination of orlistat in biological matrices using experimental design

  2024cites this paper
• Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV

  2024cites this paper
• State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics.

  2024cites this paper
• Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084

  2024influential citation
• Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen

  2023cites this paper
• Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

  2023cites this paper
• Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots.

  2023cites this paper
• A Retrospective Analysis of Preclinical and Clinical Pharmacokinetics from Administration of Long-Acting Aqueous Suspensions

  2023influential citation
• HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic

  2023cites this paper
• Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.

  2023cites this paper
• Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase

  2023cites this paper
• Formulation of Cabotegravir Loaded Gold Nanoparticles: Optimization, Characterization to In-Vitro Cytotoxicity Study

  2022cites this paper
• Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.

  2022cites this paper
• Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance

  2022cites this paper
• Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254

  2022cites this paper
• A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model

  2022cites this paper
• Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

  2022cites this paper
• A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP

  2022cites this paper
• Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV

  2022cites this paper
• Long-Acting Cabotegravir for HIV/AIDS Prophylaxis.

  2021cites this paper
• Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir

  2021cites this paper
• Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study

  2021cites this paper
• Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083.

  2021cites this paper
• Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

  2021cites this paper
• HIV-1 integrase strand transfer inhibitors: A review of current drugs, recent advances and drug resistance.

  2021cites this paper
• The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

  2021cites this paper
• Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.

  2021cites this paper
• Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis

  2021cites this paper
• Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic

  2021cites this paper
• A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery

  2020cites this paper
• Cabotegravir Plus Rilpivirine: First Approval

  2020cites this paper
• The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study

  2020cites this paper
• An evaluation of cabotegravir for HIV treatment and prevention

  2020cites this paper
• Design and testing of a cabotegravir implant for HIV prevention.

  2020cites this paper
• Long-acting injectable cabotegravir for the prevention of HIV infection.

  2020cites this paper
• Advances in Long-Acting Agents for the Treatment of HIV Infection

  2020cites this paper
• Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

  2020cites this paper
• HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

  2020cites this paper
• Placental Transfer of the integrase strand inhibitors cabotegravir and bictegravir in the Ex-Vivo Human Cotyledon Perfusion Model.

  2020influential citation
• Integrative Clinical and Practical Hematology Highlights of Antiretroviral Therapy for Adults and Adolescents Patients with HIV Infection in the Technological Era

  2019cites this paper
• HIV Treatment Strategies – The role of integrase strand transfer inhibitors

  2019cites this paper
• Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

  2019cites this paper
• Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential

  2019cites this paper
• Long-Acting HIV Drugs for Treatment and Prevention.

  2019cites this paper
• A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls

  2019cites this paper
• 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.

  2019cites this paper
• A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants

  2019cites this paper
• Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential

  2019cites this paper
• Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

  2019cites this paper
• HIV_A_184642 179..192

  2019cites this paper
• Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis

  2018cites this paper
• Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor

  2018cites this paper
• Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase

  2018cites this paper
• Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1

  2018influential citation
• Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery.

  2018cites this paper
• Pharmaceutical Approaches to HIV Treatment and Prevention

  2018cites this paper
• Modern Human Immunodeficiency Virus Therapy: Progress and Prospects

  2018cites this paper
• Treatment and prevention of HIV infection with long-acting antiretrovirals

  2018influential citation
• Where are we with injectables against HIV infection and what are the remaining challenges?

  2018cites this paper
• In Vitro Antiviral Activity of Cabotegravir against HIV-2

  2018cites this paper
• The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection

  2017cites this paper
• Cardiovascular risk and dyslipidemia among persons living with HIV: a review

  2017cites this paper
• Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251

  2017cites this paper
• Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

  2017cites this paper
• Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

  2017cites this paper
• Long acting systemic HIV pre-exposure prophylaxis: an examination of the field

  2017cites this paper
• Investigational HIV integrase inhibitors in phase I and phase II clinical trials

  2017cites this paper
• Long-Acting Antiretrovirals: Where Are We now?

  2017cites this paper
• Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

  2017cites this paper
• The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA

  2016cites this paper
• Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

  2016cites this paper
• Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review

  2016cites this paper
• Current status and prospects of HIV treatment.

  2016cites this paper
• Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects

  2016cites this paper
• Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam

  2016cites this paper
• The promise and pitfalls of long-acting injectable agents for HIV prevention

  2016cites this paper
• Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date

  2016cites this paper
• Towards a rational design of solid drug nanoparticles with optimised pharmacological properties

  2016cites this paper
• Characterizing Class‐Specific Exposure‐Viral Load Suppression Response of HIV Antiretrovirals Using A Model‐Based Meta‐Analysis

  2016cites this paper
• Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda

  2015cites this paper
• Andrews 1..9

  2015cites this paper
• Long-acting antiviral agents for HIV treatment

  2015cites this paper
• The Application of Nanotechnology to Drug Delivery in Medicine

  2015cites this paper
• Hiv Integrase Mechanisms Of Resistance To Raltegravir, Elvitegravir, And Dolutegravir

  2015cites this paper
• Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention

  2015cites this paper
• Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.

  2015cites this paper
• Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection

  2015cites this paper
• A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

  2015cites this paper
• Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.

  2015cites this paper
• The clinical role and cost-effectiveness of long-acting antiretroviral therapy.

  2015cites this paper
• Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

  2015cites this paper